Anti-TIM-1 Monoclonal Antibody (RMT1-10) Attenuates Atherosclerosis By Expanding IgM-producing B1a Cells
Hamid Hosseini, Li Yi, Peter Kanellakis, Cao Anh, Christopher Tay, Karlheinz Peter, Alex Bobik, Ban-Hock Toh, Tin Kyaw
JOURNAL OF THE AMERICAN HEART ASSOCIATION | WILEY | Published : 2018
BACKGROUND: Peritoneal B1a cells attenuate atherosclerosis by secreting natural polyclonal immunoglobulin M (IgM). Regulatory B cells expressing T-cell immunoglobulin mucin domain-1 (TIM-1) expanded through TIM-1 ligation by anti-TIM-1 monoclonal antibody (RMT1-10) induces immune tolerance. METHODS AND RESULTS: We examined the capacity of RMT1-10 to expand peritoneal B1a cells to prevent atherosclerosis development and retard progression of established atherosclerosis. RMT1-10 treatment selectively doubled peritoneal B1a cells, tripled TIM-1+ B1a cells and increased TIM-1+IgM+interleukin (IL)-10+ by 3-fold and TIM-1+IgM+IL-10- B1a cells by 2.5-fold. Similar expansion of B1a B cells was obser..View full abstract
Awarded by National Health and Medical Research Council of Australia
This study is supported by the National Health and Medical Research Council of Australia (project grant APP1066896 funding to Kyaw) and the National Heart Foundation of Australia (a PhD postgraduate scholarship to Hosseini) and is supported, in part, by the Victorian Government's Operational Infrastructure Support Program.